Literature DB >> 16192633

Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.

Quan Lin1, Raymond Lai, Lucian R Chirieac, Changping Li, Vilmos A Thomazy, Ioannis Grammatikakis, George Z Rassidakis, Wei Zhang, Yasushi Fujio, Keita Kunisada, Stanley R Hamilton, Hesham M Amin.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) has oncogenic potential. The biological effects of STAT3 have not been studied extensively in the pathogenesis of colon cancer, nor has the role of Janus kinase 3 (JAK3), the physiological activator of STAT3, been evaluated. Here, we demonstrate that activated STAT3 (pSTAT3) and activated JAK3 (pJAK3) are expressed constitutively in two colon cancer cell lines, SW480 and HT29. To evaluate the significance of JAK3/STAT3 signaling, we inhibited JAK3 with AG490 and STAT3 with a dominant-negative construct. Inhibition of JAK3 down-regulated pSTAT3. The blockade of JAK3/STAT3 signaling significantly decreased viability of colon cancer cells due to apoptosis and cell-cycle arrest through down-regulation of Bcl-2, Bcl-X(L), Mcl-1, and cyclin D2 and up-regulation of p21(waf1/cip1) and p27(kip1). We also examined histological sections from 22 tumors from patients with stage II or stage IV colon cancer and found STAT3, JAK3, and their activated forms to be frequently expressed. Furthermore, quantitative reverse transcriptase-polymerase chain reaction identified JAK3 mRNA in colon cancer cell lines and primary tumors. Our findings illustrate the biological importance of JAK3/STAT3 activation in the oncogenesis of colon cancer and provide novel evidence that JAK3 is expressed and contributes to STAT3 activation in this malignant neoplasm.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192633      PMCID: PMC1603671          DOI: 10.1016/S0002-9440(10)61187-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

Review 1.  STAT proteins and transcriptional responses to extracellular signals.

Authors:  C M Horvath
Journal:  Trends Biochem Sci       Date:  2000-10       Impact factor: 13.807

Review 2.  STAT-signalling through the cytoplasmic compartment: consideration of a new paradigm.

Authors:  P B Sehgal
Journal:  Cell Signal       Date:  2000-08       Impact factor: 4.315

3.  Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells.

Authors:  X Leschelle; S Delpal; M Goubern; H M Blottière; F Blachier
Journal:  Eur J Biochem       Date:  2000-11

4.  Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.

Authors:  K W Eriksen; K Kaltoft; G Mikkelsen; M Nielsen; Q Zhang; C Geisler; M H Nissen; C Röpke; M A Wasik; N Odum
Journal:  Leukemia       Date:  2001-05       Impact factor: 11.528

Review 5.  The role of STATs in transcriptional control and their impact on cellular function.

Authors:  J Bromberg; J E Darnell
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

6.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.

Authors:  D Sinibaldi; W Wharton; J Turkson; T Bowman; W J Pledger; R Jove
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

7.  STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1).

Authors:  J P de Koning; A A Soede-Bobok; A C Ward; A M Schelen; C Antonissen; D van Leeuwen; B Löwenberg; I P Touw
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

8.  Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival.

Authors:  J Odajima; I Matsumura; J Sonoyama; H Daino; A Kawasaki; H Tanaka; N Inohara; T Kitamura; J Downward; K Nakajima; T Hirano; Y Kanakura
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

9.  beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.

Authors:  L Huang; A B Pardee
Journal:  Mol Med       Date:  1999-11       Impact factor: 6.376

10.  Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil.

Authors:  M E Nita; S K Ono-Nita; N Tsuno; O Tominaga; T Takenoue; E Sunami; J Kitayama; Y Nakamura; H Nagawa
Journal:  Jpn J Cancer Res       Date:  2000-08
View more
  87 in total

1.  Construction of recombinant adenovirus carrying GRIM19 and its effect on SW480 cells.

Authors:  Shen Wang; Guihua Wang; Yu Deng; Xuelai Luo; Xiaolan Li; Deding Tao; Jianping Gong; Junbo Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-02

2.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

3.  ING4 enhances paclitaxel's effect on colorectal cancer growth in vitro and in vivo.

Authors:  Liyu Cao; Shunhua Chen; Cong Zhang; Cong Chen; Nana Lu; Yan Jiang; Yongping Cai; Yu Yin; Jianming Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  Association between STAT3 polymorphisms and cancer risk: a meta-analysis.

Authors:  Ruicheng Yan; Fusheng Lin; Chao Hu; Shilun Tong
Journal:  Mol Genet Genomics       Date:  2015-06-11       Impact factor: 3.291

5.  Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6.

Authors:  Hirokazu Ohtaki; Tomoya Nakamachi; Kenji Dohi; Yoichi Aizawa; Atsushi Takaki; Kei Hodoyama; Sachiko Yofu; Hitoshi Hashimoto; Norihito Shintani; Akemichi Baba; Manfred Kopf; Yoichiro Iwakura; Kouhei Matsuda; Akira Arimura; Seiji Shioda
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

6.  Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis.

Authors:  Jayshree Mishra; Raj K Verma; Gianfranco Alpini; Fanyin Meng; Narendra Kumar
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

7.  Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

Authors:  Nelson Ung; Tracy L Putoczki; Stanley S Stylli; Irvin Ng; John M Mariadason; Timothy A Chan; Hong-Jian Zhu; Rodney B Luwor
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

8.  NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.

Authors:  Byung-Hak Kim; Jun-Goo Jee; Chang-Hong Yin; Claudio Sandoval; Somasundaram Jayabose; Daisuke Kitamura; Erika A Bach; Gyeong-Hun Baeg
Journal:  Mol Cancer       Date:  2010-02-11       Impact factor: 27.401

9.  Suppressor of cytokine signaling 3 (SOCS3) is not an independent biomarker of colorectal adenoma risk.

Authors:  Kathryn E Hamilton; P Kay Lund; Joseph A Galanko; Robert S Sandler; Temitope O Keku
Journal:  BMC Res Notes       Date:  2010-05-25

10.  Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling.

Authors:  Viktor Chesnokov; Chao Sun; Keiichi Itakura
Journal:  Cancer Cell Int       Date:  2009-09-10       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.